Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man ≥ 18 years~* Body mass index (BMI) ≥ 19 and ≤ 40 kg/m2.~* Has a planned unilateral inguinal herniorrhaphy (open laparotomy, tension free technique) to be performed according to standard surgical technique under general anesthesia.~Exclusion Criteria:~* Has a known hypersensitivity to amide local anesthetics, opioids, or bovine products.~* Scheduled for bilateral inguinal herniorrhaphy.~* Undergone a prior herniorrhaphy on the side scheduled for repair.~* Undergone major surgery within 3 mos of the scheduled herniorrhaphy.~* Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.~* Concomitantly uses antiarrhythmics (eg, amiodarone, lidocaine), propranolol, or strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and grapefruit juice).~* Used long acting analgesics within 24 hours of surgery. Short acting analgesics such as acetaminophen may be used on the day of surgery but are subject to preoperative restrictions for oral intake.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2, 5x5cm bupivacaine collagen sponges (Type: EXPERIMENTAL): collagen sponges
- 2, Placebo collagen sponges (Type: PLACEBO_COMPARATOR): Placebo collagen sponges

Based on this trial design, predict the completion outcome and termination type (if applicable).